Skip to content

MBX Biosciences, Inc. MBX Change in Lease Liabilities

Change in Lease Liabilities at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
-$139K-7.8%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$327K+45.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$1.85M-26.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$205K+112%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$685K+24.1%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$349K-13.7%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s change in lease liabilities?
MBX Biosciences, Inc. (MBX) reported change in lease liabilities of -$41K in Q1 2026.
How has MBX Biosciences, Inc.'s change in lease liabilities changed year-over-year?
MBX Biosciences, Inc.'s change in lease liabilities increased by 2.4% year-over-year, from -$42K to -$41K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.